Director Aida Habtezion filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on November 10, 2026, reporting her initial ownership position in Azora Therapeutics, Inc. as of the event date of November 3, 2026.

Key Highlights

  • Reporting person: Aida Habtezion, identified in the filing as a Director of Azora Therapeutics, Inc.
  • Event date: The date of the event requiring the statement is listed as November 3, 2026.
  • No securities reported: According to the filing, "No securities are beneficially owned" - both Table I (non-derivative securities) and Table II (derivative securities) contain no entries.
  • Issuer: Azora Therapeutics, Inc. (DE), trading on NASDAQ:AZR.
  • Signed by attorney-in-fact: The form was signed by Matthew Davidson as Attorney-in-Fact on November 10, 2026, with a Power of Attorney attached as Exhibit 24.

Habtezion Reports No Beneficial Ownership at Time of Becoming Azora Director

Aida Habtezion submitted a Form 3 to the SEC on November 10, 2026, covering the period beginning with an event date of November 3, 2026. The filing identifies her as a Director of Azora Therapeutics, Inc. (DE), listed on NASDAQ:AZR. The company's address of record provided in the filing is 16501 Ventura Blvd., Suite 400, Encino, California 91436.

As required when an individual first becomes subject to Section 16(a) reporting obligations, the Form 3 discloses all securities beneficially owned at the time the reporting obligation arises. In this case, the filing states explicitly that "No securities are beneficially owned." Both Table I, covering non-derivative securities, and Table II, covering derivative securities such as options, warrants, and convertible instruments, are blank with no entries reported.

The form was filed by one reporting person and was signed by Matthew Davidson as Attorney-in-Fact, with the filing noting that Exhibit 24, a Power of Attorney, is attached. The form type is listed as an initial statement, not an amendment.

What Was Disclosed

Azora Therapeutics director Aida Habtezion filed an initial beneficial ownership statement on November 10, 2026, disclosing that she held no direct or indirect beneficial ownership of any securities of Azora Therapeutics, Inc. as of the November 3, 2026 event date.